Epidemiology of attention deficit hyperactive disorder

Last updated

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulty focusing attention, hyperactivity, and impulsive behavior. [1] Treatments generally involve behavioral therapy and/or medications (stimulants and non-stimulants). [2] ADHD is estimated to affect about 6 to 7 percent of people aged 18 and under when diagnosed via the DSM-IV criteria. [3] However, these estimates may be inaccurate as females tend to have fewer symptoms, as identified in the DSM-IV, and thus tend to be under-diagnosed due to these sex differences in predicting ADHD. [4] [5] When diagnosed via the ICD-10 criteria, hyperkinetic disorder (the ICD-10 term for severe ADHD) gives rates between 1 and 2 percent in this age group. [6] [7]

Contents

Children in North America appear to have a higher rate of ADHD than children in Africa and the Middle East — however, this may be due to differing methods of diagnosis used in different areas of the world. [8] If the same diagnostic methods are used rates are more or less the same between countries. [9]

Africa

In 2020, a meta-analysis of studies found that 7.47% of children and adolescents across Africa have ADHD. [10] ADHD was found more often in boys, at a rate of 2:1. [10] The most common form of ADHD was inattentive (2.95% of total population), followed by hyperactive/impulsive (2.77%), then combined (2.44%). [10] While differences in prevalence rate were found internationally, it is not clear whether this reflects true differences or changes in methodology. [10]

Asia

The estimated prevalence of childhood ADHD in Asia is less than 5%, which is similar to its prevalence in South America, Europe, North America, and Oceania. [8] The estimated prevalence of adult ADHD is 25.66% in the South-East Asia Region and 9.67% in the Western Pacific Region. [11] Amongst both children and adolescents, 67 studies have shown that an estimated prevalence rate of ADHD within Mainland China, Taiwan, and Hong Kong is 6.3%. The data collected from these regions suggest differences in cultural, geographical, and socioeconomic backgrounds. [12]

China

Utilizing data from the WHO World Mental Health (WMH) Surveys, it is estimated that, in China (Shenzhen), the prevalence of childhood ADHD is 0.7% and the prevalence of adult ADHD is 1.8%. [13] This study also determined that for adults in China (Shenzhen) with existing ADHD, 62.8% had a history of childhood ADHD. [13] Variability in the ADHD prevalences of children in China can be attributed to differences in study methodology, socioeconomics, and dates of data collection. [14] The prevalence of ADHD diagnosis in China could be explained by the one-child rule that had affected China's population, and thus could have had psychological effects on children, resulting in behavioral issues. Additionally, the competitive environment in the Chinese education system can result in high levels of stress amongst school-aged children, which can lead to various mental problems such as ADHD. [12]

India

The estimated prevalence of childhood ADHD in India is 7.1%, with individual study estimates ranging from 1.30% to 28.9%. [15] Male children in India exhibited a slightly higher ADHD prevalence of 9.40% compared to 5.20% in female children. [15] Overall, the prevalence of childhood ADHD in India does not differ significantly from the global prevalence, but there may be additional stigma associated with mental disorders in India. [15]

Middle East

The estimated prevalence of ADHD in Arab countries among schoolchildren (ages 6–12 years) ranges between 7.8 and 11.1%, while it was higher, at 16%, in studies that included younger children (ages 3 to 15 years). This variation was primarily explained by methodological differences between studies. [16] However, all studies in various Arab countries revealed a male predominance of ADHD.

Saudi Arabia

The prevalence of attention deficit hyperactivity disorder was found to be 3.4% overall in Riyadh, Saudi Arabia, among primary school students between the years of 2015 and 2016, with 22 children having symptoms that were both reported by their parents and teachers. The gender split among them was 3:1, with 13 (5.7%) boys and 9 (2.1%) girls. [17]

Iran

A systemic review of studies carried out in various Iranian cities between January 1990 and December 2018 revealed a prevalence of ADHD that ranged from 3.17% to 17.3%. [18] Overall, boys (5.03% to 29%) had higher numbers [19] compared to girls (2.3% to 15%).[ citation needed ]

Iraq

The prevalence rate of ADHD was found to be 8.67% in a cross-sectional study done in Tikrit City, Iraq in 2012–2013 among students in 6 primary schools for boys and girls. Male to female ratio was 1.87:1, and boys made up the majority of those affected (65%). 49% of them were younger than 9 years old. In this study, the inattention subtype was most prevalent (38%) followed by combined (34%) and hyperactive (28%). [20]

Lebanon

Between March 2012 and December 2012, a cross-sectional survey of 510 Arabic-speaking adolescents aged 11 to 17 years and 11 months who resided in Beirut found that 52 (10.20%) of the sample had been diagnosed with ADHD, of which 77% had the combined type and 6% had the inattentive type. 35 (67.31%) of those diagnosed were male, and 49 (94.23%) were Lebanese citizens. [21]

Qatar

Results from a cross-sectional study in Qatar Independent and Private Schools revealed that boys between the ages of 6 and 9 exhibited the most ADHD symptoms, with 16.36% of them scoring higher than the 5% threshold for the disorder on the SNAP-IV, standardized rating scale, as opposed to only 4.13% of girls in the same age group. 12.32% of the boys between the ages of 10 and 12 who took the SNAP test showed ADHD symptoms above the 5% cutoff point, and 6.08% of the girls had symptoms severe enough to warrant a clinical assessment for ADHD. In Qatari schools, the average percentage of students aged 6 to 19 with ADHD symptoms was 8.3%. [22]

Australia

The Australian Institute of Health and Welfare reports that the most recent national data on childhood and adolescent mental health (gathered in 2013–14) demonstrated that the prevalence of ADHD was 8.2% in children aged 4–11 and 6.3% in adolescents aged 12–17. [23] Severe disorders were more common among boys (10.9%) than girls (5.4%). [24] In comparison to females aged 4–11 years, the prevalence of ADHD was lower in females aged 12–17 years (2.7% vs. 5.4%), although it was roughly the same in males (9.8% vs. 10.9%). [24] An association with household income was also discovered for ADHD, with the odds of a child or adolescent being diagnosed with ADHD being 1.5 times higher in families in the lowest tercile of household income compared to those in the highest tercile. [25] The prevalence of childhood ADHD in Oceania does not significantly differ from South America, North America, Europe, and Asia. [8]

Europe

Germany

A 2008 evaluation of the “KiGGS” survey, monitoring 14,836 girls and boys (age between 3 and 17 years), showed that 4.8% of the participants had an ADHD diagnosis. While 7.9% of all boys had ADHD, only 1.8% girls had it, too. Another 4.9% of the participants (6.4% boys : 3.6% girls) were suspected ADHD cases, because they showed a rate ≥7 on the Strengths and Difficulties Questionnaire (SDQ) scale. The number of ADHD diagnoses was 1.5% (2.4% : 0.6%) among preschool children (3–6 years old), 5,3 % (8.7% : 1.9%) at age 7–10 years, and had its peak at 7.1% (11.3% : 3.0%) in the age group of 11–13 years. Among 14 to 17 years old adolescents the rate was 5.6% (9.4% : 1.8%). [26]

France

The prevalence of residents of France with ADHD is estimated to be between 3.5-5.6% of youth. The number of male children in France who have been diagnosed with ADHD is higher than the number of female children diagnosed with the disorder. Children with an ADHD diagnosis have been shown to be more likely to have difficulties in school settings, and have struggled to maintain higher grades. [27]

Spain

ADHD has a prevalence rate of around 5-12% in children residing in Spain. The rate for adults in Spain is an estimated 0.5-5%. The reason for this low estimated prevalence rate of ADHD in adults could be due to underreported numbers within the older age range. [28] Rates in Spain are estimated at 6.8% among people under 18. [29]

United Kingdom

Estimates of the prevalence of childhood ADHD in the United Kingdom (UK) ranges from 0.2% to 2.2%, varying by the study methodology. [30] [31] [32] The estimated adult ADHD prevalence in the UK is 0.1%. [33] [30] In some parts of England, there were waiting lists of five years or more for ADHD adult diagnostic assessment in 2019. [34]

North America

Percent of United States youth 4-17 ever diagnosed with ADHD as of 2007 .mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{} 14%-15.9% 11%-13.9% 9.6%-10.9% 8.0%-9.5% 5.6%-7.9% ADHD Prevalence.svg
Percent of United States youth 4–17 ever diagnosed with ADHD as of 2007
  14%–15.9%
  11%–13.9%
  9.6%–10.9%
  8.0%–9.5%
  5.6%–7.9%
Percent of United States youth 4-17 ever diagnosed with ADHD as of 2003 ADHDUSMap.jpg
Percent of United States youth 4–17 ever diagnosed with ADHD as of 2003

In the United States it is diagnosed in roughly 7 million children aged 3-17, with boys being 15% more likely to be diagnosed than girls at 8%. [36] The prevalence of ADHD within the age group of 5-11 years for both male and female children is 8.6%, whereas children in the age group of 12-17 years is 14.3%. [37] This difference between genders may reflect either a difference in susceptibility or that females with ADHD are less likely to be diagnosed than males. [38] The rates of diagnosis and treatment of ADHD are much higher on the east coast of the United States than on its west coast. [39] This difference between genders may reflect either a difference in susceptibility or that females with ADHD are less likely to be diagnosed than males. [38] Boys outnumber girls across all three subtyping categories, but the exact magnitude of these differences seems to depend on both the informant (parent, teacher, etc.) and the subtype. In two community-based investigations, conducted by DuPaul and associates, boys outnumbered girls by only 2.2:1 in parent-generated samples and 2.3:1 in teacher-based input. [40]

South America

The estimated prevalence of symptomatic adult ADHD in the Region of the Americas (North America and South America) is 6.06%. [11] The estimated prevalence of childhood ADHD in South America is 11.8%. [8] [41] This is not significantly different from North America, Europe, Oceania, or Asia. [41] [8] The estimated childhood ADHD prevalences for Colombia, Peru, and Brazil are 1.2%, 0.8%, and 2.5% respectively. [13] The estimated adult ADHD prevalences for Colombia, Peru, and Brazil are 2.5%, 1.4%, and 5.9% respectively. [13]

Changing rates

Rates of ADHD diagnosis and treatment have increased in both the United Kingdom and the United States since the 1970s. This is believed to be primarily due to changes in how the condition is diagnosed [42] and how readily people are willing to treat it with medications rather than a true change in the frequency. [6] In the UK an estimated 0.5 per 1,000 children had ADHD in the 1970s, while 3 per 1,000 received ADHD medications in the late 1990s. In the UK in 2003, 3.6 percent of male children and less than 1 percent in female children had the diagnosis. [43] : 134  In the United States the number of children with the diagnosis increase from 12 per 1000 in the 1970s to 34 per 1000 in the late 1990s, [43] to 95 per 1,000 in 2007, [44] and 110 per 1,000 in 2011. [45] It is believed that the changes to the diagnostic criteria in 2013 from the DSM 4TR to the DSM 5 will increase the number of people with ADHD especially among adults. [46]

Related Research Articles

<span class="mw-page-title-main">Attention deficit hyperactivity disorder</span> Neurodevelopmental disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and developmentally-inappropriate.

<span class="mw-page-title-main">Conduct disorder</span> Developmental disorder

Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself through a repetitive and persistent pattern of behavior that includes theft, lies, physical violence that may lead to destruction, and reckless breaking of rules, in which the basic rights of others or major age-appropriate norms are violated. These behaviors are often referred to as "antisocial behaviors", and is often seen as the precursor to antisocial personality disorder; however, the latter, by definition, cannot be diagnosed until the individual is 18 years old. Conduct disorder may result from parental rejection and neglect and can be treated with family therapy, as well as behavioral modifications and pharmacotherapy. Conduct disorder is estimated to affect 51.1 million people globally as of 2013.

<span class="mw-page-title-main">Methylphenidate</span> Central nervous system stimulant

Methylphenidate, sold under the brand names Ritalin and Concerta among others, is a central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy. It is a first-line treatment for ADHD ; it may be taken by mouth or applied to the skin, and different formulations have varying durations of effect. For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines, alleviating the executive functioning deficits of sustained attention, inhibition, working memory, reaction time and emotional self-regulation.

Developmental disorders comprise a group of psychiatric conditions originating in childhood that involve serious impairment in different areas. There are several ways of using this term. The most narrow concept is used in the category "Specific Disorders of Psychological Development" in the ICD-10. These disorders comprise developmental language disorder, learning disorders, developmental coordination disorders, and autism spectrum disorders (ASD). In broader definitions, attention deficit hyperactivity disorder (ADHD) is included, and the term used is neurodevelopmental disorders. Yet others include antisocial behavior and schizophrenia that begins in childhood and continues through life. However, these two latter conditions are not as stable as the other developmental disorders, and there is not the same evidence of a shared genetic liability.

<span class="mw-page-title-main">Conditions comorbid to autism</span> Medical conditions more common in autistic people

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that begins in early childhood, persists throughout adulthood, and is characterized by difficulties in social communication and restricted, repetitive patterns of behavior. There are many conditions comorbid to autism spectrum disorder, such as attention deficit hyperactivity disorder, anxiety disorders, and epilepsy.

Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood, except for when ADHD occurs after traumatic brain injury. Specifically, multiple symptoms must be present before the age of 12, according to DSM-5 diagnostic criteria. The cutoff age of 12 is a change from the previous requirement of symptom onset, which was before the age of 7 in the DSM-IV. This was done to add flexibility in the diagnosis of adults. ADHD was previously thought to be a childhood disorder that improved with age, but recent research has disproved this. Approximately two-thirds of childhood cases of ADHD continue into adulthood, with varying degrees of symptom severity that change over time and continue to affect individuals with symptoms ranging from minor inconveniences to impairments in daily functioning.

Child psychopathology refers to the scientific study of mental disorders in children and adolescents. Oppositional defiant disorder, attention-deficit hyperactivity disorder, and autism spectrum disorder are examples of psychopathology that are typically first diagnosed during childhood. Mental health providers who work with children and adolescents are informed by research in developmental psychology, clinical child psychology, and family systems. Lists of child and adult mental disorders can be found in the International Statistical Classification of Diseases and Related Health Problems, 10th Edition (ICD-10), published by the World Health Organization (WHO) and in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association (APA). In addition, the Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood is used in assessing mental health and developmental disorders in children up to age five.

DAMP is a psychiatric concept conceived by Christopher Gillberg defined by the presence of five properties: problems of attention, gross and fine motor skills, perceptual deficits, and speech-language impairments. While routinely diagnosed in Scandinavian countries, the diagnosis has been rejected in the rest of the world. Minor cases of DAMP are roughly defined as a combination of developmental coordination disorder (DCD) and a pervading attention deficit.

Cognitive disengagement syndrome (CDS) is a syndrome characterized by developmentally-inappropriate, impairing and persistent levels of decoupled attentional processing from the ongoing external context and resultant hypoactivity. Symptoms often manifest in difficulties with staring, mind blanking, withdrawal, mental confusion and maladaptive mind wandering alongside delayed, sedentary or slow motor movements. To scientists in the field, it has reached the threshold of evidence and recognition as a distinct syndrome.

Oppositional defiant disorder (ODD) is listed in the DSM-5 under Disruptive, impulse-control, and conduct disorders and defined as "a pattern of angry/irritable mood, argumentative/defiant behavior, or vindictiveness." This behavior is usually targeted toward peers, parents, teachers, and other authority figures, including law enforcement officials. Unlike conduct disorder (CD), those with ODD do not generally show patterns of aggression towards random people, violence against animals, destruction of property, theft, or deceit. One-half of children with ODD also fulfill the diagnostic criteria for ADHD.

<span class="mw-page-title-main">Russell Barkley</span> American psychologist and author (born 1949)

Russell Alan BarkleyFAPA is a retired American clinical neuropsychologist who was a clinical professor of psychiatry at the VCU Medical Center until 2022 and president of Division 12 of the American Psychological Association (APA) and of the International Society for Research in Child and Adolescent Psychopathology. Involved in research since 1973 and a licensed psychologist since 1977, he is an expert on attention-deficit hyperactivity disorder (ADHD) and has devoted much of his scientific career to studying ADHD and related fields like childhood defiance. He proposed the renaming of sluggish cognitive tempo (SCT) to cognitive disengagement syndrome (CDS).

Attention deficit hyperactivity disorder predominantly inattentive, is one of the three presentations of attention deficit hyperactivity disorder (ADHD). In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R). In DSM-5, subtypes were discarded and reclassified as presentations of the same disorder that change over time.

<span class="mw-page-title-main">Attention deficit hyperactivity disorder controversies</span> Controversies surrounding the topic of ADHDs nature, diagnosis, and treatment

Despite the scientifically well-established nature of attention deficit hyperactivity disorder (ADHD), its diagnosis, and its treatment, each of these has been controversial since the 1970s. The controversies involve clinicians, teachers, policymakers, parents, and the media. Positions range from the view that ADHD is within the normal range of behavior to the hypothesis that ADHD is a genetic condition. Other areas of controversy include the use of stimulant medications in children, the method of diagnosis, and the possibility of overdiagnosis. In 2009, the National Institute for Health and Care Excellence, while acknowledging the controversy, stated that the current treatments and methods of diagnosis are based on the dominant view of the academic literature.

Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD. Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training, neurofeedback, neurostimulation, physical exercise, nutrition and supplements, integrative medicine, parent support, and school interventions. Based on two 2024 systematic reviews of the literature, FDA-approved medications and to a lesser extent psychosocial interventions have been shown to improve core ADHD symptoms compared to control groups.

Child and adolescent psychiatry is a branch of psychiatry that focuses on the diagnosis, treatment, and prevention of mental disorders in children, adolescents, and their families. It investigates the biopsychosocial factors that influence the development and course of psychiatric disorders and treatment responses to various interventions. Child and adolescent psychiatrists primarily use psychotherapy and/or medication to treat mental disorders in the pediatric population.

Joseph Biederman was an American academic psychiatrist. He was Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School.

The Pediatric Attention Disorders Diagnostic Screener (PADDS), created by Dr. Thomas K. Pedigo and Kenneth L. Pedigo, is a suite of computer administered neuropsychological tests of attention and executive functioning. The PADDS is used in the diagnosis of attention deficit hyperactivity disorder (ADHD) in children between the ages of 6 and 12 years. The PADDS software program represents a multi-dimensional, evidence-based approach to ADHD assessment, consisting of the Computer Administered Diagnostic Interview (CADI), the Swanson, Nolan, and Pelham—IV (SNAP-IV) Parent and Teacher rating scales, and the three computer-administered objective measures of the Target Tests of Executive Functioning (TTEF). It calculates a diagnostic likelihood ratio, where each data source is allowed to contribute to (or detract from) the prediction of the diagnosis, as well as normalized relative standard scores, t-scores, z-scores, and percentile ranks for comparison to the non-clinical reference group.

<span class="mw-page-title-main">Disruptive mood dysregulation disorder</span> Medical condition

Disruptive mood dysregulation disorder (DMDD) is a mental disorder in children and adolescents characterized by a persistently irritable or angry mood and frequent temper outbursts that are disproportionate to the situation and significantly more severe than the typical reaction of same-aged peers. DMDD was added to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a type of depressive disorder diagnosis for youths. The symptoms of DMDD resemble many other disorders, thus a differential includes attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), anxiety disorders, and childhood bipolar disorder, intermittent explosive disorder (IED), major depressive disorder (MDD), and conduct disorder.

The Vanderbilt ADHD Diagnostic Rating Scale (VADRS) is a psychological assessment tool for attention deficit hyperactivity disorder (ADHD) symptoms and their effects on behavior and academic performance in children ages 6–12. This measure was developed by Mark L Wolraich at the Oklahoma Health Sciences Center and includes items related to oppositional defiant disorder, conduct disorder, anxiety, and depression, disorders often comorbid with ADHD.

The ADHD Rating Scale (ADHD-RS) is a parent-report or teacher-report inventory created by George J. DuPaul, Thomas J. Power, Arthur D. Anastopoulos, and Robert Reid consisting of 18–90 questions regarding a child's behavior over the past 6 months. The ADHD Rating Scale is used to aid in the diagnosis of attention deficit hyperactivity disorder (ADHD) in children ranging from ages 5–17.

References

  1. ↑ CDC (2021-01-26). "What is ADHD?". Centers for Disease Control and Prevention. Retrieved 2022-09-18.
  2. ↑ CDC (2020-09-21). "Treatment of ADHD | CDC". Centers for Disease Control and Prevention. Retrieved 2022-09-18.
  3. ↑ Willcutt EG (July 2012). "The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review". Neurotherapeutics. 9 (3): 490–9. doi:10.1007/s13311-012-0135-8. PMC   3441936 . PMID   22976615.
  4. ↑ Quinn PO, Madhoo M (2014). "A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis". Prim Care Companion CNS Disord. 16 (3) PCC.13r01596. doi:10.4088/PCC.13r01596. PMC   4195638 . PMID   25317366.
  5. ↑ Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H (April 2019). "Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment". Eur Child Adolesc Psychiatry. 28 (4): 481–9. doi:10.1007/s00787-018-1211-3. PMC   6445815 . PMID   30097723.
  6. 1 2 Cowen P (2012). Shorter Oxford Textbook of Psychiatry (6th ed.). Oxford University Press. p. 546. ISBN   978-0-19-162675-3 . Retrieved 2014-01-17. Cited source of Cowen (2012): Taylor E (2012). "Attention deficit and hyperkinetic disorders in childhood and adolescence". New Oxford Textbook of Psychiatry (2nd ed.). pp. 1644–54. doi:10.1093/med/9780199696758.003.0215. ISBN   978-0-19-969675-8.
  7. ↑ Cameron M, Hill P (May 1996). "Hyperkinetic disorder: assessment and treatment". Advances in Psychiatric Treatment. 2 (3): 94–102. doi:10.1192/apt.2.3.94. ISSN   1355-5146.
  8. 1 2 3 4 5 Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–8. doi:10.1176/appi.ajp.164.6.942. PMID   17541055.
  9. ↑ Tsuang M, Tohen M, Jones PB, eds. (2011). Textbook of psychiatric epidemiology (3rd ed.). Wiley-Blackwell. p. 450. ISBN   978-0-470-97740-8. OCLC   769189342.
  10. 1 2 3 4 Ayano G, Yohannes K, Abraha M (2020-03-13). "Epidemiology of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Africa: a systematic review and meta-analysis". Annals of General Psychiatry. 19 (1): 21. doi: 10.1186/s12991-020-00271-w . PMC   7071561 . PMID   32190100.
  11. 1 2 Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I (2021-02-11). "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis". Journal of Global Health. 11: 04009. doi:10.7189/jogh.11.04009. ISSN   2047-2986. PMC   7916320 . PMID   33692893.
  12. 1 2 Liu A, Xu Y, Yan Q, Tong L (2018-08-16). "The Prevalence of Attention Deficit/Hyperactivity Disorder among Chinese Children and Adolescents". Scientific Reports. 8 (1): 11169. doi:10.1038/s41598-018-29488-2. ISSN   2045-2322.
  13. 1 2 3 4 Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Borges G, de Girolamo G, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Lee S (March 2017). "The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys". Attention Deficit and Hyperactivity Disorders. 9 (1): 47–65. doi:10.1007/s12402-016-0208-3. ISSN   1866-6647. PMC   5325787 . PMID   27866355.
  14. ↑ A L, Y X, Q Y, L T (2018-08-16). "The Prevalence of Attention Deficit/Hyperactivity Disorder among Chinese Children and Adolescents". Scientific Reports. 8 (1): 11169. Bibcode:2018NatSR...811169L. doi:10.1038/s41598-018-29488-2. ISSN   2045-2322. PMC   6095841 . PMID   30115972.
  15. 1 2 3 Joseph J, Devu B (2019). "Prevalence of attention-deficit hyperactivity disorder in India: A systematic review and meta-analysis". Indian Journal of Psychiatric Nursing. 16 (2): 118. doi: 10.4103/IOPN.IOPN_31_19 . ISSN   2231-1505. S2CID   210867045.
  16. ↑ Alhraiwil NJ, Ali A, Househ MS, Al-Shehri AM, El-Metwally AA (2015). "Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries". Neurosciences. 20 (2): 137–144. doi:10.17712/nsj.2015.2.20140678. PMC   4727626 . PMID   25864066.
  17. ↑ Albatti TH, Alhedyan Z, Alnaeim N, Almuhareb A, Alabdulkarim J, Albadia R, Alshahrani K (2017). "Prevalence of attention deficit hyperactivity disorder among primary school-children in Riyadh, Saudi Arabia; 2015–2016". International Journal of Pediatrics and Adolescent Medicine. 4 (3): 91–94. doi:10.1016/j.ijpam.2017.02.003. PMC   6372494 . PMID   30805508.
  18. ↑ Hakim Shooshtari M, Shariati B, Kamalzadeh L, Naserbakht M, Tayefi B, Taban M (2021-04-30). "The prevalence of attention deficit hyperactivity disorder in Iran: An updated systematic review". Medical Journal of the Islamic Republic of Iran. 35: 8. doi:10.47176/mjiri.35.8. PMC   8111633 . PMID   33996659.
  19. ↑ Mohammadi M, Ahmadi N, Salmanian M, Arman S, Khoshhal Dastjerdi J, Ghanizadeh A, Alavi A, Malek A, Fathzadeh Gharibeh H, Moharreri F, Hebrani P, Motavallian A (2015). "Psychiatric Disorders in Iranian Children and Adolescents: Application of the Kiddie-sads-present and Lifetime Version (K-sads-pl)" . European Psychiatry. 30: 688. doi:10.1016/s0924-9338(15)30544-7. ISSN   0924-9338. S2CID   74259034.
  20. ↑ "Prevalence of Attention Deficit Hyperactivity Disorder among Primary School Children in Tikrit City, Iraq" . Al-Anbar Medical Journal. 17 (1): 25–29. 2021-06-01. doi:10.33091/AMJ.1101622020. S2CID   242964710.
  21. ↑ Ghossoub E, Ghandour LA, Halabi F, Zeinoun P, Shehab AA, Maalouf FT (2017). "Prevalence and correlates of ADHD among adolescents in a Beirut community sample: results from the BEI-PSY Study". Child and Adolescent Psychiatry and Mental Health. 11 (1): 20. doi: 10.1186/s13034-017-0156-5 . PMC   5393010 . PMID   28428817.
  22. ↑ Bradshaw LG, Kamal M (2017). "Prevalence of ADHD in Qatari School-Age Children". Journal of Attention Disorders. 21 (5): 442–9. doi:10.1177/1087054713517545. ISSN   1087-0547. PMID   24412969. S2CID   23778696.
  23. ↑ "Australia's youth: Mental illness". Australian Institute of Health and Welfare. 25 June 2021. Retrieved 2022-09-16.
  24. 1 2 "Health of children". Australian Institute of Health and Welfare. Retrieved 2022-09-16.
  25. ↑ Lawrence D, Hafekost J, Johnson SE, Saw S, Buckingham WJ, Sawyer MG, Ainley J, Zubrick SR (2016). "Key findings from the second Australian Child and Adolescent Survey of Mental Health and Wellbeing". Australian & New Zealand Journal of Psychiatry. 50 (9): 876–886. doi:10.1177/0004867415617836. ISSN   0004-8674. PMID   26644606. S2CID   19863662.
  26. ↑ "Erkennen — Bewerten — Handeln: Zur Gesundheit von Kindern und Jugendlichen in Deutschland" (PDF) (in German). Robert Koch Institute. 27 November 2008. Archived from the original (PDF; 3,27 MB) on 11 December 2013. Retrieved 24 February 2014. — Kapitel 2.8 Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS), S. 57 ISBN   978-3-89606-109-6. See also Schlack R, Hölling H, Kurth BM, Huss M (May 2007). "Die Prävalenz der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern und Jugendlichen in Deutschland" (PDF). Bundesgesundheitsblatt — Gesundheitsforschung — Gesundheitsschutz (in German). 50 (5–6). Robert Koch Institute: 827–35. doi:10.1007/s00103-007-0246-2. PMID   17514469. S2CID   9311463. Archived from the original (PDF) on 24 February 2014.
  27. ↑ Lecendreux M, Konofal E, Faraone SV (2011-08). "Prevalence of attention deficit hyperactivity disorder and associated features among children in France". Journal of Attention Disorders. 15 (6): 516–524. doi:10.1177/1087054710372491. ISSN   1557-1246. PMID   20679156.{{cite journal}}: Check date values in: |date= (help)
  28. ↑ Ramos-Quiroga JA, Richarte V, Soto I, Targhetta M, Ward J, Perulero N (2023-02). "The Prevalence and Treatment of ADHD in Spain: A Retrospective Cohort Analysis". Journal of Attention Disorders. 27 (3): 273–282. doi:10.1177/10870547221136226. ISSN   1557-1246. PMID   36373564.{{cite journal}}: Check date values in: |date= (help)
  29. ↑ Catalá-López F, Peiró S, Ridao M, Sanfélix-Gimeno G, Gènova-Maleras R, Catalá MA (October 2012). "Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies". BMC Psychiatry. 12: 168. doi: 10.1186/1471-244X-12-168 . PMC   3534011 . PMID   23057832.
  30. 1 2 Young S, Asherson P, Lloyd T, Absoud M, Arif M, Colley WA, Cortese S, Cubbin S, Doyle N, Morua SD, Ferreira-Lay P, Gudjonsson G, Ivens V, Jarvis C, Lewis A (2021). "Failure of Healthcare Provision for Attention-Deficit/Hyperactivity Disorder in the United Kingdom: A Consensus Statement". Frontiers in Psychiatry. 12: 649399. doi: 10.3389/fpsyt.2021.649399 . ISSN   1664-0640. PMC   8017218 . PMID   33815178.
  31. ↑ Ford T, Goodman R, Meltzer H (October 2003). "The British Child and Adolescent Mental Health Survey 1999: The Prevalence of DSM-IV Disorders". Journal of the American Academy of Child & Adolescent Psychiatry. 42 (10): 1203–11. doi:10.1097/00004583-200310000-00011. PMID   14560170.
  32. ↑ Sayal K, Ford T, Goodman R (August 2010). "Trends in Recognition of and Service Use for Attention-Deficit Hyperactivity Disorder in Britain, 1999–2004". Psychiatric Services. 61 (8): 803–810. doi:10.1176/ps.2010.61.8.803. ISSN   1075-2730. PMID   20675839.
  33. ↑ Raman SR, Man KK, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE (October 2018). "Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases". The Lancet Psychiatry. 5 (10): 824–835. doi:10.1016/S2215-0366(18)30293-1. PMID   30220514. S2CID   52280020.
  34. ↑ "Clearing ADHD caseload could take 5 years, CCG warns". Health Service Journal. 25 January 2019. Retrieved 2 March 2019.
  35. ↑ "CDC – ADHD, Prevalence – NCBDDD". 2017-02-13.
  36. ↑ CDC (2024-10-23). "Data and Statistics on ADHD". Attention-Deficit / Hyperactivity Disorder (ADHD). Retrieved 2024-11-18.
  37. ↑ "Products - Data Briefs - Number 499 - March 2024". www.cdc.gov. 2024-03-15. Retrieved 2024-11-18.
  38. 1 2 Staller J, Faraone SV (2006). "Attention-deficit hyperactivity disorder in girls: epidemiology and management". CNS Drugs. 20 (2): 107–23. doi:10.2165/00023210-200620020-00003. PMID   16478287. S2CID   25835322.
  39. ↑ Centers for Disease Control and Prevention (October 17, 2013). "ADHD Home". United States: CDC.gov.
  40. ↑ Anastopoulos AD, Shelton, TL (2001). Assessing attention-deficit/hyperactivity disorder. New York, NY: Kluwer. ISBN   978-0-306-47512-2. OCLC   757107540.
  41. 1 2 Moffitt TE, Melchior M (June 2007). "Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter?". The American Journal of Psychiatry. 164 (6): 856–8. doi:10.1176/ajp.2007.164.6.856. ISSN   0002-953X. PMC   1994964 . PMID   17541041.
  42. ↑ "ADHD Throughout the Years" (PDF). Center For Disease Control and Prevention. Retrieved 2 August 2013.
  43. 1 2 National Institute for Health and Clinical Excellence (24 September 2008). "CG72 Attention deficit hyperactivity disorder (ADHD): full guideline" (PDF). NHS.
  44. ↑ "Attention-Deficit / Hyperactivity Disorder (ADHD): Data and Statistics". Centers for Disease Control and Prevention. May 13, 2013.
  45. ↑ Schwarz A (Mar 31, 2013). "A.D.H.D. Seen in 11% of U.S. Children as Diagnoses Rise". New York Times. Retrieved 2 August 2013.
  46. ↑ Dalsgaard S (February 2013). "Attention-deficit/hyperactivity disorder (ADHD)". European Child & Adolescent Psychiatry. 22 (Suppl 1): S43-8. doi:10.1007/s00787-012-0360-z. PMID   23202886. S2CID   23349807.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.